The solvent-polarity dependence and temporal characteristics of the transient absorption of 4-(dimethylamino)benzonitrile, DMABN, and 4-(dimethylamino)benzethyne, DMABE, demonstrate the presence of the πσ*-state absorption at about 700 nm and the ππ* (LE)-state absorption at about 520 nm and 450 nm. The rise and decay times of the πσ*-state transient differ from those of the ππ*-state transients in both compounds. Moreover, the peak position of the πσ*-state absorption is blue-shifted and more intense in acetonitrile as compared to n-hexane, whereas the band positions of the ππ*-state absorptions are essentially the same in the two solvents. For DMABN in acetonitrile, the rise time (∼4.3 ps) of the twisted intramolecular charge transfer (TICT)-state transient at 330 nm is identical to the decay time of the πσ*-state transient. The 4.8 ns decay time of the TICT-state absorption of DMABN is longer than the 2.9 ns decay time of the intramolecular charge-transfer (ICT) fluorescence, indicating that the fluorescent ICT state differs from the TICT state observed in transient absorption. These results are consistent with the presence of a low-lying πσ* state in DMABN (and DMABE), and the role the πσ* state plays in the formation of the TICT state of DMABN.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c0cp02706e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The microtubule-severing enzyme spastin regulates spindle dynamics to promote chromosome segregation in .
bioRxiv
January 2025
Department of Microbiology and Molecular Genetics, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030.
Microtubule-severing enzymes play essential roles in regulating diverse cellular processes, including mitosis and cytokinesis, by modulating microtubule dynamics. In the early branching protozoan parasite , microtubule-severing enzymes are involved in cytokinesis and flagellum length control during different life cycle stages, but none of them have been found to regulate mitosis in any life cycle form. Here, we report the biochemical and functional characterization of the microtubule-severing enzyme spastin in the procyclic form of .
View Article and Find Full Text PDFPEX1 remains functional in peroxisome biogenesis but is rapidly degraded by the proteasome.
bioRxiv
December 2024
Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.
The PEX1/PEX6 AAA-ATPase is required for the biogenesis and maintenance of peroxisomes. Mutations in and disrupt peroxisomal matrix protein import and are the leading cause of Peroxisome Biogenesis Disorders (PBDs). The most common disease-causing mutation in PEX1 is the PEX1 allele, which results in a reduction of peroxisomal protein import.
View Article and Find Full Text PDFEvaluation of cephalosporin allergy: Survey of drug allergy experts.
J Allergy Clin Immunol Glob
February 2025
Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Background: Since the publication of the 2022 Drug Allergy Practice Parameters (DAPP) of the American Academy of Allergy, Asthma & Immunology (AAAAI) and American College of Allergy, Asthma & Immunology (ACAAI), it is unclear the extent to which the simplified and risk-stratified evaluation of cephalosporin allergy has been incorporated into allergy practice.
Objective: We aimed to assess current cephalosporin allergy testing practices using real case examples.
Methods: An 18-question REDCap survey was sent to the 136 members of the Adverse Reactions to Drugs, Biologics and Latex (ARDBL) Committee of the AAAAI between February and April 2023.
The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology.
J Allergy Clin Immunol
January 2025
Section of Allergy and Clinical Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo. Electronic address:
Omalizumab was recently approved by the US Food and Drug Administration for treatment of any single food allergy or multiple food allergies in children aged 1 year and older and adults. There is currently no formal guidance regarding recommended best practices for omalizumab use in food allergy, including patient selection, anticipated goals and outcomes of therapy, procedure for monitoring patients who elect to start omalizumab therapy, and ways in which omalizumab can be incorporated into the landscape of food allergy management and daily clinical practice. This work group report was developed by the food allergy therapies subcommittee of the Adverse Reactions to Foods Committee within the American Academy of Allergy, Asthma & Immunology.
View Article and Find Full Text PDFAddressing health disparities in food allergy: A Position Statement of the AAAAI Prior Authorization Task Force.
J Allergy Clin Immunol
January 2025
American Academy of Allergy, Asthma & Immunology (AAAAI), Milwaukee, Wis.
Self-reported food allergies (FAs) affect approximately 8% of the US pediatric and approximately 10% of the adult population, which reflects potentially disproportionate increases among ethnically and racially minoritized groups. Multiple gaps and unmet needs exist regarding FA disparities. There is reported evidence of disparities in FA outcomes, and the FA burden may also be disproportionate in low-income families.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!